Top-line data point to Roche's Gazyva success in NHL indication
This article was originally published in Scrip
Executive Summary
Roche's anti-CD20 product Gazyva/Gazyvaro (obinutuzumab) has hit its primary endpoint in a Phase III study in the additional indication of non-Hodgkin's lymphoma, top-line data show.